SecBot SecBot
ANALYST-UPGRADE

BIIB

BIOGEN INC.
MIXED
Impact 3/10
Horizonmonths Processed6mo ago SECanalyst-BIIB-ubs-20260422
UBS double upgrade: Neutral → Buy
Actionable Insight ◆ Mixed

Contrarian upgrade from a low-accuracy firm ahead of earnings adds noise, not signal. Wait for post-earnings clarity given mixed institutional flows and declining EPS revisions. The $225 PT is aggressive relative to fundamentals unless guidance surges.

DirectionMixed
Confidencemedium
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$190.12
T+0 close · Apr 22, 2026 · via day close
Latest settled
+9.89%
T+60 · $208.92
Vs SPY
+4.33%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 22 $190.12entry
  2. T+1 · 7mo ago −1.20%α −0.81% · $187.84
  3. T+5 · 7mo ago +0.14%α +0.09% · $190.39
  4. T+20 · 6mo ago +0.23%α −2.93% · $190.56
  5. T+60 · 4mo ago +9.89%α +4.33% · $208.92
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

UBS double upgraded NVDA from Neutral to Buy with a new $225 PT, representing 21% upside from current levels. The move follows Wells Fargo and Piper Sandler upgrades in the past two weeks. Consensus remains mixed with only 40% Buy-rated (20/50), below average conviction. UBS’s accuracy is 50% (1/2), below peer median of 55%. Analyst momentum is positive: 3 upgrades in 30 days, 0 downgrades. EPS estimates are trending down over 30 days: -2 net revisions. Institutional activity shows divergence, FMR doubled down while Renaissance trimmed -58.6%. Earnings due in 7 days. Contrarian call from low-accuracy firm ahead of event limits conviction.

Impact Score

Base Score
2/7
LLM Adjustment
+1
Final Score
3/10

Consensus & Targets

Buy / Strong Buy
20 (47%)
Hold
22
Sell / Strong Sell
1
Total Analysts
30
Mean PT
$209.36
Median PT
$206.50
High PT
$275.00
Low PT
$150.00
Current Price
$185.95
Implied Upside
+12.6%

Of 50 total analysts, 20 rate Buy/Strong Buy (40%), 22 Hold (44%), 2 Sell/Strong Sell (4%). Consensus is below average in bullishness compared to sector median of 52% Buy ratings. Directionally, consensus is shifting slightly positive with 3 upgrades in the last 30 days and no downgrades.

Consensus price target is $209.36 (mean), $206.50 (median), with a high of $275 and low of $150. Current price is $185.95, implying 12.5% upside to mean. UBS’s $225 PT is 7.2% above the mean and 9.1% above median, placing it in the top quartile of targets. Prior UBS PT was $185, now 21.6% higher.

Recent Analyst Activity

DateFirmActionRatingPrice Target
2026-04-22UBSupgradeBuy$225.00
2026-04-20Wells FargoupgradeOverweight$250.00
2026-04-14Piper SandlerupgradeOverweight$214.00
2026-04-13CitigroupmaintainNeutral$190.00
2026-04-13Truist SecuritiesmaintainHold$189.00
2026-04-10Morgan StanleymaintainEqual-Weight$200.00
2026-04-02HC Wainwright & Co.maintainBuy$237.00
2026-04-01Canaccord GenuitymaintainBuy$245.00
2026-04-01OppenheimermaintainOutperform$275.00
2026-03-17HSBCmaintainReduce$150.00

In the past 30 days, 3 analysts upgraded NVDA, 0 downgraded. EPS revisions show negative momentum: over 30 days, +1 up, -3 down for current quarter; +3 up, -3 down for next year. Current quarter EPS estimate has declined from $3.04 to $3.01, suggesting weakening near-term expectations despite stock upgrades.

Firm Track Record: UBS

UBS accuracy: 55% on 5083 calls | avg return: 4.6%

Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 15 firms with ≥5 scored calls.

FirmAccuracyCallsAvg Returnvs Average
Jefferies100%2/213%top tier
Morgan Stanley83%5/65.5%top tier
Piper Sandler71%5/71.6%top tier
Wedbush67%4/62.1%top tier
JP Morgan67%2/32.5%top tier
HC Wainwright & Co.57%4/71.4%above average
UBS50%1/20.6%below average
Barclays50%2/4-2.8%below average
Canaccord Genuity50%1/2-2.1%below average
Goldman Sachs50%1/2-0.1%below average

UBS has a 50% accuracy rate (1 correct out of 2 rated calls) with an average return of +0.6%, ranking below average among 15 covering firms. The median firm accuracy is 55% (2,806/5,083). Top performers include Jefferies (100%, 2/2) and Morgan Stanley (83%, 5/6). UBS’s track record adds limited weight to this call.

Earnings Estimates

Next earnings: Apr 29, 2026

PeriodEPS Est.EPS RangeRevenueRevisions (7d)
+1q$4.36$3.95 to $5.04$2.4B↑1 ↓0
+1y$15.83$14.34 to $17.60$9.3B↑2 ↓0
0q$3.01$1.66 to $4.68$2.3B↑1 ↓0
0y$15.58$14.02 to $16.33$9.5B↑1 ↓0

Cross-Platform Signals

Congressional
Gilbert Cisneros (democrat): buy $1,001 - $15,000
Institutional
NORGES BANK: new
Institutional
FMR LLC: doubled (632%)
Institutional
WELLS FARGO & COMPANY/MN: trim (-32.3%)
Short Interest
Short: 341,571 | Exempt: 178 | TRF Vol: 579,253 | Short Ratio: 59.0% | Off-exchange volume (dark pool + OTC)

Institutional activity is split: FMR LLC doubled position (+632%), Norges Bank initiated new $464M stake, and UBS Group added +35.1%. But Renaissance Technologies cut -58.6% and Wells Fargo & Co. trimmed -32.3%. No insider trades reported. Congressional buys: one small buy by Rep. Cisneros ($1K–$15K). Short interest is elevated at 59.0% short ratio, indicating high bearish positioning ahead of earnings.

Investment Themes

Documents Analyzed

Report based on filing metadata.

Track record

34 reports on BIIB

Performance horizon

10 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +15.73% at T+60 after the Jul 13, 2026 report. 16 of 17 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Neutral 3/10 Entry $253.40 Now $251.65 −0.69% settles Feb 11
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $253.25 Now $251.65 −0.63% settles Feb 8
  3. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $254.87 Now $251.65 −1.26% settles Feb 5
  4. Oct 28, 202619d ago Institutional Cluster Neutral 2/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
  5. Oct 28, 202619d ago 8-K Bullish 6/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
  6. Oct 19, 202628d ago Press Release Neutral 4/10 Entry $233.48 Now $251.65 +7.78% settles Jan 14
  7. Oct 12, 20265w ago ANALYST-UPGRADE Bullish 6/10 Entry $229.41 Now $251.65 +9.69% settles Jan 7
  8. Oct 2, 20266w ago Press Release Bullish 6/10 Entry $219.88 Now $251.65 +14.45% settles Dec 29
  9. Sep 17, 20268w ago Press Release Bullish 5/10 Entry $215.50 Now $251.65 +16.77% settles Dec 14
  10. Sep 3, 202610w ago Press Release Neutral 4/10 Entry $220.83 Now $251.65 +13.96% settles Dec 1
Showing 10 of 34

US Market Status

Market Closed · Opens Wed (11h 19m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 22, 2026